Merrill keeps Vertex at neutral

Vertex Pharmaceuticals Inc. maintained its neutral rating by Merrill Lynch analyst Hari Sambasivam. The company reported fourth-quarter 2005 financial results with total revenues of $63.8 million, including royalties of $9.7 million, compared with the analyst's estimates of $54.6 million and $9.6 million. Vertex ended the quarter with cash of $407.5 million and debt of $160.1 million. Shares of the Cambridge, Mass., biotechnology company were up 82 cents, or 2.27%, at $36.93 on volume of 1,967,943 shares versus the three-month running average of 1,415,060 shares. (Nasdaq: VRTX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.